December 10, 2022 11:30 AM EST
R&D
Pharma
Cell/Gene Tx

#ASH22: J&J touts first PhII re­sults of next-gen mul­ti­ple myelo­ma an­ti­body

Kyle LaHucik

Senior Reporter

NEW OR­LEANS — A day af­ter sub­mit­ting its ap­pli­ca­tion to the FDA to use its drug tal­que­tam­ab for treat­ment of re­lapsed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Akero re­deems its fail­ure in se­vere MASH with longer-term da­ta

UK biotech launch­es with T cell ther­a­py tech­nol­o­gy to treat sol­id tu­mors

Maze looks to lead IPO queue with $113M Nas­daq de­but

Ex­clu­sive: Leerink builds health­care M&A team, poach­ing deal­mak­ers from ri­vals

Ei­sai and Bio­gen win ap­proval for once-month­ly Leqem­bi main­te­nance dos­ing

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times